HT
NBIX icon

HAP Trading’s Neurocrine Biosciences NBIX Stock Holding History

HAP Trading’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-45,500
Closed -$677K – 850
2025
Q1 		$677K Buy
+45,500
New +$5.76M 0.07% 153
2024
Q4 		– Sell
-13,600
Closed -$119K – 810
2024
Q3 		$119K Buy
+13,600
New +$1.86M 0.01% 377
2017
Q3 		– Sell
-38,300
Closed -$32K – 1005
2017
Q2 		$32K Buy
+38,300
New +$1.86M ﹤0.01% 742
2015
Q1 		– Sell
-200,800
Closed -$53K – 1127
2014
Q4 		$53K Buy
+200,800
New +$3.8M ﹤0.01% 723

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HAP Trading's NBIX Position: Q2 2025 in Review

HAP Trading sold out of Neurocrine Biosciences (NBIX) in Q2 2025, closing a stake of 35,884 shares — an estimated $3.97M sold.

HAP Trading first reported a position in NBIX in Q1 2025 and held it in 1 quarter. The position peaked at $3.97M in Q1 2025. 586 funds tracked by Wall St. Rank hold NBIX as of Q2 2025.

  • HAP Trading reported no remaining Neurocrine Biosciences position as of Q2 2025 after selling out during the quarter.
  • HAP Trading sold 35,884 Neurocrine Biosciences shares in Q2 2025, an estimated $3.97M.
  • HAP Trading first reported a position in Neurocrine Biosciences in Q1 2025 and held it in 1 quarter.
  • HAP Trading's Neurocrine Biosciences position peaked at $3.97M in Q1 2025.
  • 586 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2025.

Based on HAP Trading's 13F filing for Q2 2025, filed 13 Aug 2025.